Veliparib联合化疗对比安慰剂联合化疗治疗BRCA1/2突变局部复发/转移性乳腺癌的随机II期研究
该随机II期研究纳入290例BRCA1/2胚系突变局部复发或转移性乳腺癌患者,按1:1:1随机接受Veliparib联合卡铂/紫杉醇(VCP)、Veliparib联合替莫唑胺(VT)或安慰剂联合卡铂/紫杉醇(PCP)。VCP较PCP在PFS和OS上呈数值增加但无统计学显著性,ORR显著提高;VT劣于PCP。
要点
- VCP组中位PFS 14.1个月 vs PCP组12.3个月(HR 0.789;95%CI 0.536-1.162;P=0.227),差异无统计学显著性。
- VCP组ORR 77.8% vs PCP组61.3%(P=0.027),差异有统计学显著性。
- VT组中位PFS 7.4个月(HR 1.858;95%CI 1.278-2.702;P=0.001),劣于PCP组。
核心结论
- VCP较PCP在PFS和OS上呈数值增加但无统计学显著性,ORR显著提高,毒性无临床意义增加;VT劣于PCP。
研究设计与样本
- 随机、1:1:1分配的II期研究,纳入290例≥18岁BRCA1/2胚系突变局部复发或转移性乳腺癌患者,284例经中心实验室确认为BRCA+。
主要发现
- VCP组中位PFS 14.1个月 vs PCP组12.3个月(HR 0.789;95%CI 0.536-1.162;P=0.227)。
- VCP组中期中位OS 28.3个月 vs PCP组25.9个月(HR 0.750;95%CI 0.503-1.117;P=0.156)。
- VCP组ORR 77.8% vs PCP组61.3%(P=0.027)。
- VT组中位PFS 7.4个月(HR 1.858;95%CI 1.278-2.702;P=0.001),中期中位OS 19.1个月(HR 1.483;95%CI 1.032-2.131;P=0.032),ORR 28.6%(P<0.001)。
- 卡铂/紫杉醇两组安全性相当;VT组中性粒细胞减少、贫血、脱发和神经病变(所有级别)发生率低于PCP组。
临床怎么用
- VCP较PCP显著提高ORR,PFS和OS呈数值增加但无统计学显著性,毒性无临床意义增加。
- VT劣于PCP,不推荐用于该患者人群。
- 一项正在进行的III期试验正在该患者人群中评估VCP对比PCP,化疗中止且无进展时可选择继续单药Veliparib/安慰剂。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Homologous recombination defects in BRCA1/2-mutated tumors result in sensitivity to poly(ADP-ribose) polymerase inhibitors, which interfere with DNA damage repair. Veliparib, a potent poly(ADP-ribose) polymerase inhibitor, enhanced the antitumor activity of platinum agents and temozolomide in early phase clinical trials. This phase II study examined the safety and efficacy of intermittent veliparib with carboplatin/paclitaxel (VCP) or temozolomide (VT) in patients with BRCA1/2-mutated breast cancer. PATIENTS AND METHODS: Eligible patients ≥18 years with locally recurrent or metastatic breast cancer and a deleterious BRCA1/2 germline mutation were randomized 1 : 1 : 1 to VCP, VT, or placebo plus carboplatin/paclitaxel (PCP). Primary end point was progression-free survival (PFS); secondary end points included overall survival (OS) and overall response rate (ORR). RESULTS: Of 290 randomized patients, 284 were BRCA+, confirmed by central laboratory. For VCP versus PCP, median PFS was 14.1 and 12.3 months, respectively [hazard ratio (HR) 0.789; 95% CI 0.536-1.162; P = 0.227], interim median OS 28.3 and 25.9 months (HR 0.750; 95% CI 0.503-1.117; P = 0.156), and ORR 77.8% and 61.3% (P = 0.027). For VT (versus PCP), median PFS was 7.4 months (HR 1.858; 95% CI 1.278-2.702; P = 0.001), interim median OS 19.1 months (HR 1.483; 95% CI 1.032-2.131; P = 0.032), and ORR 28.6% (P < 0.001). Safety profile was comparable between carboplatin/paclitaxel arms. Adverse events (all grades) of neutropenia, anemia, alopecia, and neuropathy were less frequent with VT versus PCP. CONCLUSION: Numerical but not statistically significant increases in both PFS and OS were observed in patients with BRCA1/2-mutated recurrent/metastatic breast cancer receiving VCP compared with PCP. The addition of veliparib to carboplatin/paclitaxel significantly improved ORR. There was no clinically meaningful increase in toxicity with VCP versus PCP. VT was inferior to PCP. An ongoing phase III trial is evaluating VCP versus PCP, with optional continuation single-agent therapy with veliparib/placebo if chemotherapy is discontinued without progression, in this patient population. CLINICAL TRIAL INFORMATION: NCT01506609.
引用
- Han HS, Diéras V, Robson M, et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Ann Oncol. 2018. PMID: 29045554. doi:10.1093/annonc/mdx505
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。